Overview

Telaprevir Open-Label Study in Co-Infected Patients

Status:
Completed
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to collect safety and tolerability data on telaprevir treatment in combination with Peg-IFN-alfa and RBV in patients with HIV/genotype 1 chronic HCV coinfection with severe fibrosis or compensated cirrhosis who are not eligible for enrollment into an ongoing clinical study of telaprevir.
Phase:
Phase 3
Details
Lead Sponsor:
Janssen-Cilag International NV
Treatments:
Ribavirin